Company profile: MDoloris
1.1 - Company Overview
Company description
- Provider of medical equipment and monitoring solutions to soothe, lessen, monitor and assess patients' pain and its impact, including ANI Monitor V2, ANI MOC-9 and HFVI MOC-9 modules for Masimo Root to measure autonomic nervous system responses, NIPETM for neonatal parasympathetic evaluation in NICU settings, and a Web academy on ANI technology.
Products and services
- NIPETM (Newborn Infant Parasympathetic Evaluation): Neonatal-specific device that measures parasympathetic tone to assess comfort and guide analgesia in NICU settings for autonomic nervous system evaluation
- ANI monitor V2: Standalone monitor measuring autonomic nervous system response and engineered robust against artifacts to support objective monitoring and assessment of patients’ pain impact
- ANI MOC-9 module: Integrated Masimo Root-compatible module enhancing autonomic nervous system measurement by embedding ANI capability within the host device for consolidated monitoring
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MDoloris
Assertio
HQ: United States
Website
- Description: Provider of pharmaceutical therapies for pain and inflammation and oncology support, offering Cambia (diclofenac potassium) for acute pain; INDOCIN oral suspension and suppositories (indomethacin); SPRIX nasal spray (ketorolac) for short-term moderate to severe pain; Otrexup (methotrexate) injection for certain cancers and autoimmune diseases; and ROLVEDON to reduce severe neutropenia in chemotherapy patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Assertio company profile →
Myoscience
HQ: United States
Website
- Description: Provider of technology-driven dermatological products, focusing on their development and commercialization; founded in 2005 and headquartered in Redwood City, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Myoscience company profile →
CoLucid
HQ: United States
Website
- Description: Provider of biotechnology therapies targeting central nervous system disorders, developing COL-144, a neurally acting anti-migraine agent for treating migraine, and COL-204, a conjugated stigmine platform producing novel chemical entities for therapy of sleep/wake disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoLucid company profile →
Brazos Biomedical
HQ: United States
Website
- Description: Provider of medical devices for pain management, developing Auracis, a head-worn device that uses transcutaneous electrical nerve stimulation (TENS) to treat migraine by targeting trigeminal and occipital nerves. Utilizes low-voltage electrical impulses to block pain signals to the brain and potentially release endorphins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Brazos Biomedical company profile →
NeurAxon
HQ: Canada
Website
- Description: Provider of pain therapeutics targeting neuronal nitric oxide synthase, discovering and developing treatments for pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeurAxon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MDoloris
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MDoloris
2.2 - Growth funds investing in similar companies to MDoloris
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MDoloris
4.2 - Public trading comparable groups for MDoloris
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →